Faculty of Pharmacy of Universidade de Lisboa (FFUL) is part of a consortium involving that was recently awarded Horizon Europe Health’s Program, with a ca. 3 million euros research grant to develop the project Vax2Muc – Next Generation Vaccines Against Gastrointestinal Mucosal Pathogens, using Helicobacter pylori as Model Pathogen. The consortium is led by the Technical University of Munich and involves 10 European universities and research institutes.
At FFUL the project is coordinated by por António J. Almeida e Lídia Gonçalves from Advanced Technologies for Drug Delivery Lab at Research Institute for Medicines (iMed.Ulisboa).
Vax2Muc’s overall aim, to improve mucosal vaccines by inducing long-term protective mucosal imune responses, will be fulfilled by pursuing two main specific objectives:
- Develop, as a proof-of-concept, a prophylactic pylori vaccine candidate and evaluate it in a clinical phase I trial;
- Advance GMP manufacturing, investigate and progress novel vaccine technologies and strategies for optimised local immunity in the GI tract.
